Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2014

01-05-2014 | Original Paper

Optimizing Content for Pre-exposure Prophylaxis (PrEP) Counseling for Men Who Have Sex with Men: Perspectives of PrEP Users and High-Risk PrEP Naïve Men

Authors: S. Wade Taylor, Kenneth H. Mayer, Steven M. Elsesser, Matthew J. Mimiaga, Conall O’Cleirigh, Steven A. Safren

Published in: AIDS and Behavior | Issue 5/2014

Login to get access

Abstract

Existing trials of antiretroviral (ARV) medication as chemoprophylaxis against HIV reveal that the degree of protection is primarily dependent on product adherence. However, there is a lack of data on targets for behavioral interventions to improve adherence to ARV as prevention. Information from individuals who have used ARV as pre-exposure prophylaxis (PrEP) can inform behavioral intervention development. Thirty-nine HIV-uninfected MSM at high risk for HIV acquisition participated in one of four semi-structured focus groups. Two of the focus groups consisted of MSM who had been prescribed and used PrEP in the context of a clinical trial; the other two consisted of high-risk MSM who had not previously used PrEP. An in-depth, within-case/across-case content analysis resulted in six descriptive themes potentially salient for a PrEP adherence behavioral intervention: (1) motivations to use PrEP, (2) barriers to PrEP use, (3) facilitators to PrEP use, (4) sexual decision-making in the context of PrEP, (5) prospective PrEP education content, and, (6) perceived effective characteristics of PrEP delivery personnel. Addressing these themes in behavioral interventions in the context of prescribing PrEP may result in the optimal “packaging” public health programs that implement PrEP for high-risk MSM.
Literature
1.
2.
Center for Disease Control and Prevention. HIV among gay and bisexual men: May 2012 Factsheet. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention: Division of HIV/AIDS Prevention. 2012.
3.
Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Presented at 20th Annual Conference on Retroviruses and Opportunist Infections; 2013 Mar 3–6; Atlanta, GA.
4.
5.
Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.PubMedCentralPubMedCrossRef
6.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCentralPubMedCrossRef
7.
Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.PubMedCentralPubMedCrossRef
8.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRef
9.
Choopanya K, Martin M, Suntharasamai, et al, for the Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized double-blind, placebo controlled phase 3 trial. Lancet 2013; published online June 13. http://​dx.​doi.​org/​10.​1016/​S0140-6736(13)61127-7.
10.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention among heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedCentralPubMedCrossRef
11.
Haberer J, Baeten J, Celum C, Katibira E, Ronald A, Tumwesigye E, et al. High adherence among HIV-1 serodiscordant couples in the partners PrEP ancillary adherence study. Presented at 7th International Conference on HIV Treatment and Prevention Adherence; 2012 Jun 3–5; Miami, FL.
12.
Safren SA, Otto MW, Worth JL. Life-Steps: applying cognitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999;6:332–41.CrossRef
13.
Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;39(10):1151–62.PubMedCrossRef
14.
Psaros C, Haberer J, Thomas K, Katabira E, Ronald A, et al. Evaluation and process outcomes from an adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda. Presented at 7th International Conference on HIV Treatment and Prevention Adherence; 2012 Jun 3–5; Miami, FL.
15.
Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;1:44–51.CrossRef
16.
Simoni JM, Chen WT, Huh D, Fredriksen-Goldsen KI, Pearson C, Zhao H, et al. A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China. AIDS Behav. 2011;15(5):919–29.PubMedCentralPubMedCrossRef
17.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedCrossRef
18.
Campbell C, Skovdal M, Mupambireyi Z, Madanhire C, Nyamukapa C, Gregson S. Building adherence-competent communities: factors promoting children’s adherence to anti-retroviral HIV/AIDS treatment in rural Zimbabwe. Health Place. 2012;18(2):123–31.PubMedCentralPubMedCrossRef
19.
Grohskopf L, Gvetadze R, Pathak S, O’Hara B, Mayer K, Liu A, et al. Phase II Clinical Safety Trial of Tenofovir Disoproxil Fumarate (TDF) for HIV-1 Pre-Exposure Prophylaxis (PrEP) Among U.S. Men who Have Sex with Men (MSM). Presented at XVIII International AIDS Conference; 2010 Jul 18–23; Vienna, Austria.
20.
Sandelowski M. What’s in a name? Qualitative description revisited. Res Nurs Health. 2010;33:77–84.PubMed
21.
Sullivan-Bolyai S, Bova C, Harper D. Developing and refining interventions in persons with health disparities: the use of qualitative description. Nurs Outlook. 2005;53(3):127–33.PubMedCrossRef
22.
Miles MB, Huberman AM. An expanded sourcebook: qualitative data analysis. 2nd ed. Thousand Oaks: SAGE; 1994.
23.
Ayres L, Kavanaugh K, Knafl KA. Within-case and across-case approaches to qualitative data analysis. Qual Health Res. 2003;13(6):871–83.PubMedCrossRef
24.
Lincoln YS, Guba EG. Naturalistic inquiry. Beverly Hills: SAGE; 1985.
25.
Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz Aa. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23(9):1136–45.PubMedCentralPubMedCrossRef
26.
Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):2039–64.CrossRef
27.
Mugavero M, Ostermann J, Whetten K, Lesserman J, Swartz M, Thielman N. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20(6):418–28.PubMedCrossRef
28.
Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256–62.PubMedCentralPubMedCrossRef
29.
Nezu A, D’Zurílla TJ. An experimental evaluation of the decision-making process in social problem solving. Cogn Ther Res. 1979;3:269–77.CrossRef
30.
Nezu A, D’Zurilla TJ. Effects of problem definition and formulation on decision-making in the social problem-solving process. Behav Ther. 1981;12:100–6.CrossRef
31.
Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4(4):165–72.PubMedCentralPubMedCrossRef
32.
Supervie V, García-Lerma JG, Heneine W, Blower S. HIV transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA. 2010;107(27):12381–6.PubMedCentralPubMedCrossRef
33.
Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.PubMedCentralPubMedCrossRef
34.
Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002–8.PubMed
35.
Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. No evidence of sexual risk compensation among HIV-uninfected men who have sex with men (MSM) participating in a tenofovir pre-exposure prophylaxis (PrEP) trial. Presented at 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 2011 Jul 17–20; Rome, Italy.
36.
Marcus J, Mayer K, Guanira J, Casapia M, Montoya O, Chariyalertsak S, et al. No Evidence of Sexual Risk Compensation in the iPrEx Trial of HIV Pre-exposure Prophylaxis. Poster presented at: 20th Annual Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3–6; Atlanta, GA.
37.
Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav. 2011;15:S72–9.PubMedCrossRef
38.
Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA. 2006;296:863–5.PubMedCrossRef
39.
Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet. 2007;370:89–93.PubMedCrossRef
40.
Strobos J, Hauschild B, Miller V. Safety Considerations in the Prevention of Transmission of HIV by Pre-Exposure Prophylaxis (or “PrEP”). Ann Forum Collab HIV Res. 2011;13(5):1–4.
41.
Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010;7:210–9.PubMedCentralPubMedCrossRef
42.
Carey MA. Comment: concerns in the analysis of focus group data. Qual Health Res. 1995;5(4):487–95.CrossRef
Metadata
Title
Optimizing Content for Pre-exposure Prophylaxis (PrEP) Counseling for Men Who Have Sex with Men: Perspectives of PrEP Users and High-Risk PrEP Naïve Men
Authors
S. Wade Taylor
Kenneth H. Mayer
Steven M. Elsesser
Matthew J. Mimiaga
Conall O’Cleirigh
Steven A. Safren
Publication date
01-05-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0617-7

Other articles of this Issue 5/2014

AIDS and Behavior 5/2014 Go to the issue

Original Paper

Evidence-Based Identification of Key Beliefs Explaining Adult Male Circumcision Motivation in Zimbabwe: Targets for Behavior Change Messaging

Brief Report

Male Circumcision Coverage, Knowledge, and Attitudes After 4-Years of Program Scale-up in Rakai, Uganda

Original Paper

Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035)

Original Paper

“Set it and Forget it”: Women’s Perceptions and Opinions of Long-Acting Topical Vaginal Gels

Original Paper

Peer Social Support is Associated with Recent HIV Testing Among Young Black Men Who Have Sex with Men

Original Paper

Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits